Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

2021

Chowdhury, Simon

Chung, Byung Ha

Gomes, Andrea Juliana Pereira de Santana

Ozguroglu, Mustafa

Uemura, Hirotsugu

Ye, Dingwei

Brookman-May, Sabine Doris

Mundle, Suneel

McCarthy, Sharon Anne

Lefresne, Florence

Dibaj, Shiva

Bevans, Katherine B.

Chi, Kim N.

Agarwal, Neeraj

Bjartell, Anders

Given, Robert

Juarez, Alvaro

Merseburger, Axel Stuart